REM-Sleep Behavior Disorder Emerges as the Strongest Marker in Early Parkinson’s Subtyping
In early Parkinson’s disease, the long-running brain-first versus body-first model is moving out of theory and into patient-level testing. A small multimodal study asked a blunt question: can the features commonly used to separate these two pathways actually classify individual patients at the bedside, rather than only distinguish groups on paper?
The answer was mixed, and clinically important. Among 20 people diagnosed within the previous two years, probable REM-sleep behavior disorder was the most useful individual marker, correctly classifying 85% of patients when 123I-MIBG scintigraphy was used as the reference standard. Other clinical and imaging features did not perform well as individual classifiers. Overlap was substantial.
Why the Brain-First and Body-First Framework Needs Individual-Level Testing
The brain-first/body-first hypothesis tries to explain where Parkinson’s begins and how it spreads. In the body-first pathway, pathology appears to start in the peripheral autonomic system, which fits with early abnormal cardiac sympathetic imaging and sleep-related brainstem dysfunction. Brain-first disease is thought to start centrally and then extend outward. The model is biologically appealing because it maps onto distinct early phenotypes, different autonomic signatures, and the heterogeneous course seen in clinic.
The problem is that group averages can make sharp categories look cleaner than they are in real patients. A biomarker that separates cohorts may still fail when used one person at a time. That distinction matters for precision medicine, where clinicians need a marker that can survive the messy overlap of early disease.
This study tested that exact weakness in the model. The cohort was limited to early Parkinson’s, within two years of diagnosis, a period when subtype assignment should matter most if the classification is truly meaningful. By anchoring the analysis to 123I-MIBG scintigraphy, a measure of cardiac sympathetic dysfunction, the investigators used a physiologic reference tied to the body-first concept rather than relying only on clinical impression.
Probable RBD Carried Most of the Individual-Level Signal
Probable RBD stood out because it aligned best with the body-first pattern defined by MIBG imaging. In practical terms, a positive sleep history did more to sort patients than the broader imaging and clinical package examined in the study. The signal is biologically plausible. RBD often reflects degeneration in brainstem structures involved in sleep atonia, and when paired with peripheral autonomic dysfunction it can fit the broader body-first sequence of disease propagation.
A one-sentence reality check is unavoidable here: the rest of the phenotype did not sort cleanly.
Other clinical and imaging features performed poorly as individual-level classifiers, and the data suggested marked overlap rather than a crisp binary split. The implication is not that the brain-first/body-first framework is wrong, but that its translation into routine patient classification is still unfinished. Early Parkinson’s may sit on a continuum, with the two trajectories blending at the edges more than the model initially implied.
Small Cohort, Strong Constraint, Narrow Clinical Reach
The study’s scale is its main limitation and also the reason the findings should be interpreted carefully. Only 20 patients were included, all early in the disease course. That is enough to test feasibility, but not enough to settle the biology or define a robust bedside algorithm. A marker that performs well in such a small cohort can still lose precision once tested across broader populations, different clinics, and more diverse disease stages.
Even so, the findings are not trivial. If probable RBD continues to track with MIBG-defined body-first disease in larger studies, sleep history may become a low-cost entry point into subtype characterization. Compared with specialized imaging, sleep symptoms are easier to obtain, cheaper to screen, and already relevant to patient care on their own. They can also be recognized before advanced biomarker testing is available, which makes them attractive for early phenotyping.
The caution is equally important. RBD is not a perfect proxy for a single underlying mechanism, and early Parkinson’s biology is unlikely to be locked into a binary classification for every patient. Autonomic failure, sleep disturbance, and nigrostriatal degeneration may evolve at different speeds, which can blur the boundaries between presumed subtypes. The study’s own results support that more fluid view by showing overlap rather than clean separation across most measures.
What This Means for Early Parkinson’s Phenotyping
Clinically, the work argues for restraint before adopting brain-first/body-first labels as fixed patient identities. The framework still has value because it links symptoms, imaging, and pathophysiology in a coherent way. But the performance of any marker has to be judged at the individual level if it is going to guide counseling, trial enrichment, or future stratified treatment.
The strongest immediate takeaway is narrow and practical: probable RBD deserves further validation as a candidate marker for body-first Parkinson’s. It may be the most accessible clue currently available, but it is not yet enough to replace more direct biomarker assessment. MIBG imaging remains the reference standard in this study, and the overlap seen in other features warns against overconfidence in single-visit phenotyping.
A more durable answer will require larger cohorts, longitudinal follow-up, and direct testing of whether these early labels predict progression, autonomic burden, cognitive decline, or response to therapy. For now, the data support a cautious conclusion: the brain-first/body-first model can be translated to individual patients only partially, and probable RBD is the clearest marker currently pointing in that direction.